{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.02","spread":"163.1050","upperLimit":"7.08","value":"2.000"},{"groupId":"OG001","lowerLimit":"2.00","spread":"140.8314","upperLimit":"7.88","value":"3.000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.","dispersionType":"Full Range","groups":[{"description":"1 year to \\< 10 years pediatric patients","id":"OG000","title":"Group 1"},{"description":"\\>= 10 years to \\<18 years pediatric patients","id":"OG001","title":"Group 2"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1, had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Summary of Nilotinib Non-compartmental PK Parameters: Tmax","type":"PRIMARY","unitOfMeasure":"h"}